Mometasone furoate: an inhaled glucocorticoid for the management of asthma in adults and children

Bibliography

• Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78
   PubMed Web of Science ®Google Scholar
• Global Initiative on Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO Workshop Report. Bethesda: National Institutes of Health, National Heart, Lung and Blood Institute, 2006
   Google Scholar
• Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol 2003;91:326-34
   PubMed Web of Science ®Google Scholar
• Bateman ED, Clark TJ, Frith L, et al. Rate of response of individual asthma control measures varies and may overestimate asthma control: an analysis of the Goal study. J Asthma 2007;44:667-73
   PubMed Web of Science ®Google Scholar
• Ward C, Pais M, Bish R, et al. Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 2002;57:309-16
   PubMed Web of Science ®Google Scholar
• Inman MD, Watson RM, Rerecich T, et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001;164:569-74
   PubMed Web of Science ®Google Scholar
• Martin RJ, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165:1377-83
   PubMed Web of Science ®Google Scholar
• Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol 2000;40:1227-36
   PubMed Web of Science ®Google Scholar
• Derendorf H, Daley-Yates PT, Pierre LN, Efthimiou J. Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology. J Clin Pharmacol 2002;42:383-7
   PubMed Web of Science ®Google Scholar
• Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 2000;55:603-13
   PubMed Web of Science ®Google Scholar
• Issar M, Sahasranaman S, Buchwald P, Hochhaus G. Differences in the glucocorticoid to progesterone receptor selectivity of inhaled glucocorticoids. Eur Respir J 2006;27:511-6
   PubMedGoogle Scholar
• Bledsoe RK, Montana VG, Stanley TB, et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002;110:93-105
   PubMed Web of Science ®Google Scholar
• Bledsoe RK, Stewart EL, Pearce KH. Structure and function of the glucocorticoid receptor ligand binding domain. Vitam Horm 2004;68:49-91
   PubMed Web of Science ®Google Scholar
• Leo JC, Guo C, Woon CT, et al. Glucocorticoid and mineralocorticoid cross-talk with progesterone receptor to induce focal adhesion and growth inhibition in breast cancer cells. Endocrinology 2004;145:1314-21
   PubMed Web of Science ®Google Scholar
• Grossmann C, Scholz T, Rochel M, et al. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol 2004;151:397-406
   PubMed Web of Science ®Google Scholar
• Austin RJ, Maschera B, Walker A, et al. Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J 2002;20:1386-92
   PubMed Web of Science ®Google Scholar
• Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007;293:L660-7
   PubMed Web of Science ®Google Scholar
• Tayab ZR, Fardon TC, Lee DK, et al. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Br J Clin Pharmacol 2007;64:698-705
   PubMed Web of Science ®Google Scholar
• Fardon TC, Lee DK, Haggart K, et al. Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate. Am J Respir Crit Care Med 2004;170:960-6
   PubMed Web of Science ®Google Scholar
• Roumestan C, Henriquet C, Bousquet J, Mathieu M. Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies. Clin Exp Allergy 2003;33:895-901
   PubMed Web of Science ®Google Scholar
• Valotis A, Hogger P. Significant receptor affinities of metabolites and a degradation product of mometasone furoate. Respir Res 2004;5:7
   PubMedGoogle Scholar
• Sahasranaman S, Issar M, Hochhaus G. Metabolism of mometasone furoate and biological activity of the metabolites. Drug Metab Dispos 2006;34:225-33
   PubMed Web of Science ®Google Scholar
• Crim C, Pierre LN, Daley-Yates PT. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001;23:1339-54
   PubMed Web of Science ®Google Scholar
• Chapman RW, Sehring SJ, Garlisi CG, et al. Anti-inflammatory activity of inhaled mometasone furoate in allergic mice. Arzneimittelforschung 1998;48:384-91
   PubMed Web of Science ®Google Scholar
• Berger WE, Milgrom H, Chervinsky P, et al. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Ann Allergy Asthma Immunol 2006;97:672-80
   PubMed Web of Science ®Google Scholar
• Meltzer E, Baena-Cagnani C, Chervinsky P, et al. Once-daily mometasone furoate administered by dry powder inhaler for the treatment of children with persistent asthma. Ped Asthma Allerg Immunol 2007;20:83-92
   Google Scholar
• Amirav I, Newhouse MT, Mansour Y. Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma. Pediatr Pulmonol 2005;39:447-51
   PubMed Web of Science ®Google Scholar
• Yang TT, Li S, Wyka B, Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 2001;14:487-94
   PubMedGoogle Scholar
• Bentur L, Mansour Y, Hamzani Y, et al. Measurement of inspiratory flow in children with acute asthma. Pediatr Pulmonol 2004;38:304-7
   PubMed Web of Science ®Google Scholar
• Kamps AW, Brand PL, Roorda RJ. Variation of peak inspiratory flow through dry powder inhalers in children with stable and unstable asthma. Pediatr Pulmonol 2004;37:65-70
   PubMedGoogle Scholar
• Bousquet J. Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma. Int J Clin Pract 2009;63:806-19
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Berkowitz RB, Chervinsky P, et al. Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999;93:603-12
   PubMed Web of Science ®Google Scholar
• Bousquet J, D'Urzo A, Hebert J, et al. Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000;16:808-16
   PubMed Web of Science ®Google Scholar
• O'Connor B, Bonnaud G, Haahtela T, et al. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001;86:397-404
   PubMed Web of Science ®Google Scholar
• Carlsson LG, Edsbacker S. Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler. Eur Respir J 2001;17:1332-3
   PubMedGoogle Scholar
• Derendorf H, Daley-Yates PT, Pierre LN, Efthimiou J. Systemic bioavailability of inhaled steroids: the importance of appropriate and comparable methodology. Eur Respir J 2001;17:157-8
   PubMedGoogle Scholar
• Lipworth BJ. Mometasone furoate levels. Chest 2001;120:1034-5
   PubMedGoogle Scholar
• Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs 2001;61:1325-50
   PubMed Web of Science ®Google Scholar
• Fish JE, Karpel JP, Craig TJ, et al. Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. J Allergy Clin Immunol 2000;106:852-60
   PubMed Web of Science ®Google Scholar
• Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol 2000;84:417-24
   PubMed Web of Science ®Google Scholar
• Kemp JP, Berkowitz RB, Miller SD, et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol 2000;106:485-92
   PubMed Web of Science ®Google Scholar
• Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001;86:36-43
   PubMed Web of Science ®Google Scholar
• Corren J, Berkowitz R, Murray JJ, Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Int J Clin Pract 2003;57:567-72
   PubMed Web of Science ®Google Scholar
• Wardlaw A, Larivee P, Eller J, et al. Efficacy and safety of mometasone furoate dry powder inhaler vs fluticasone propionate metered-dose inhaler in asthma subjects previously using fluticasone propionate. Ann Allergy Asthma Immunol 2004;93:49-55
   PubMed Web of Science ®Google Scholar
• Chrousos GP, Ghaly L, Shedden A, et al. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest 2005;128:70-7
   PubMed Web of Science ®Google Scholar
• Mortimer KJ, Harrison TW, Tang Y, et al. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. Br J Clin Pharmacol 2006;62:412-9
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Allen DB. Evaluation of tests of hypothalamic-pituitary-adrenal axis function used to measure effects of inhaled corticosteroids. Ann Allergy Asthma Immunol 2007;98:118-27
   PubMedGoogle Scholar
• Mortimer KJ, Harrison TW, Tattersfield AE. Effects of inhaled corticosteroids on bone. Ann Allergy Asthma Immunol 2005;94:15-21
   PubMedGoogle Scholar
• Leone FT, Fish JE, Szefler SJ, West SL. Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. Chest 2003;124:2329-40
   PubMed Web of Science ®Google Scholar
• Garrott HM, Walland MJ. Glaucoma from topical corticosteroids to the eyelids. Clin Experiment Ophthalmol 2004;32:224-6
   PubMed Web of Science ®Google Scholar
• Breton MC, Beauchesne MF, Lemiere C, et al. Risk of perinatal mortality associated with asthma during pregnancy. Thorax 2009;64:101-6
   PubMed Web of Science ®Google Scholar
• NAEEP Expert Panel Report. Expert Panel Report 3 (EPR-3): guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94-138
   PubMed Web of Science ®Google Scholar
• Bensch GW, Prenner B, Berkowitz R, et al. Once-daily evening administration of mometasone furoate in asthma treatment initiation. Ann Allergy Asthma Immunol 2006;96:533-40
   PubMed Web of Science ®Google Scholar
• D'Urzo A, Karpel JP, Busse WW, et al. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. Curr Med Res Opin 2005;21:1281-9
   PubMed Web of Science ®Google Scholar
• Karpel JP, Busse WW, Noonan MJ, et al. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Ann Pharmacother 2005;39:1977-83
   PubMed Web of Science ®Google Scholar
• Beeh KM, Derom E, Kanniess F, et al. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J 2007;29:871-8
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008;9:73
   PubMed Web of Science ®Google Scholar